Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01375985 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Single Administration Intravenous Treatment for Influenza
A Phase 1 study, sponsored by Sarepta Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01375985: Clinical Trial Phase 1 study, sponsored by Sarepta Therapeutics.
NCT01375985 is a Phase 1 study that was terminated before completion, run by Sarepta Therapeutics. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01375985, a Phase 1 study, was terminated before completion, sponsored by Sarepta Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-7100, a candidate treatment for influenza.
Interventions
- DRUG Placebo
- DRUG AVI-7100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Why NCT01375985 stopped before completion
NCT01375985 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01375985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01375985 about?
NCT01375985 is a clinical study titled "Safety Study of Single Administration Intravenous Treatment for Influenza". The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-7100, a candidate treatment for influenza.
What is the current status of trial NCT01375985?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2011-06. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01375985?
The interventions under investigation include: Placebo (DRUG), AVI-7100 (DRUG).
Who is sponsoring clinical trial NCT01375985?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01375985's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia